Immunai
Maps the immune system with AI and multi-omic analysis.. [Contact for Pricing]
Last verified:
What is Immunai?
Immunai is a biotechnology AI platform that decodes the immune system using single-cell multi-omic data to guide therapeutic discovery. The company partners with top biopharmaceutical companies like AstraZeneca and Teva, as well as research institutions, to discover and advance novel therapeutics. Immunai produces high-quality multiomic data from clinical and preclinical samples using cutting-edge wet lab and computational pipelines, transforming them into a uniform single-cell data foundation with unmatched resolution.
The platform's core is AMICA, the world's largest cell-level immune knowledge base, containing 5-6k studies (350+ single-cell studies), 800+ cell types (80 immune cell types), 500+ diseases, and 300K+ patient samples. AMICA provides deep multiomic single-cell profiling of clinical cohorts, dynamic functional genomics for multiplexed perturbations, broad curated data from public sources, and unified clinical and immunological annotations for integrative analysis. The Immunodynamics Engine (IDE) computes novel immune features, linking immune mechanisms to treatment responses and outcomes through advanced machine learning.
Immunai's workflow includes five steps: Generate (producing multiomic data), Augment (enriching with AMICA database), Compute (leveraging ML to link mechanisms to outcomes), Validate (using functional genomics to validate hypotheses in the lab), and Recommend (providing clear actionable paths forward). The platform delivers high-resolution immune profiles including single-cell RNA sequencing, 80+ surface proteins via CITE-seq, and TCR repertoire sequencing. It is used for target discovery, trial optimization (patient stratification, dose selection), validating therapeutic hypotheses, prioritizing trial arms or patient subgroups, and identifying candidate patient stratification biomarkers.
The tool is designed for biopharmaceutical companies, research institutions, and clinical centers working on drug discovery and development, particularly in oncology and inflammatory diseases. It helps prioritize trial arms, validate therapeutic hypotheses with deep mechanistic insight, add confidence to preclinical efficacy and safety evaluation, and identify targets with the highest potential for therapeutic impact. Immunai also offers a Grand Collaboration Initiative for academic research centers.
Immunai pricing
Pricing model: Freemium
Enterprise/collaboration-based pricing with custom contracts via partnerships with biopharma. No public free tier available - access is through partnership or contracted collaborations. Immunai has secured $300M in funding and has multi-year partnerships including AstraZeneca (up to $37.5M during 2026-2027 for oncology, plus $85M deal for inflammatory bowel disease). The Grand Collaboration Initiative offers free single-cell multi-omics sequencing for academic centers (100-1,000+ samples), where Immunai covers sequencing costs but partners cover sample collection, regulatory fees, shipping, and insurance. This is a data-for-data in-kind partnership pending Immunai approval.
Immunai pros
- World's largest immune-focused single-cell database (AMICA) with 300K+ patient samples
- Single-cell resolution with 1,500+ genes per cell transcriptomic coverage
- 80+ surface protein markers via CITE-seq proteomic profiling
- TCR repertoire sequencing for lineage tracking
- Vertically integrated platform from sample processing to insight derivation
- Fully automated computational pipeline for reproducibility
- Links immune mechanisms to treatment responses and outcomes
- Validates ML-driven hypotheses in the lab using functional genomics
- Explainable scoring showing why immune signals tie to clinical outcomes
- Partnerships with top biopharma including AstraZeneca and Teva
- Identifies rare cell types and decouples complex cell states
- Correlates immune surrogate endpoints with clinical endpoints
- Harmonizes data from multiple sources for integrative analysis
- Supports biomarker discovery across 500+ diseases
- Goes from correlation to causation through functional genomics validation
- High-throughput lab processing 100-1,000+ samples
- Unified clinical and immunological annotations for analysis
Immunai cons
- No public free tier - access only via partnership or contracted collaboration
- Enterprise/collaboration-based pricing with custom contracts only
- Grand Collaboration Initiative open to non-commercial academic research only
- Requires minimum 500K viable cells for PBMC samples
- Sample collection, shipping, and regulatory fees not covered for partners
- Timeline flexible but depends on Immunai's internal resource availability
- Prioritizes projects with sufficient samples, may exclude smaller studies
- Primary focus on immune system may limit non-immunology applications
Frequently asked questions about Immunai
What does Immunai do?
Immunai decodes the immune system using single-cell biology and AI to power new therapeutic discoveries. The platform generates high-quality multiomic data from clinical and preclinical samples, enriches it with AMICA (the world's largest immune-focused single-cell database), computes novel immune features using machine learning to link mechanisms to outcomes, validates hypotheses in the lab using functional genomics, and provides actionable recommendations for drug discovery and development.
What is AMICA?
AMICA (Annotated Multiomic Immune Cell Atlas) is the world's largest cell-level immune knowledge base and clinical genomic database for measuring the human immune system. It contains 5-6k studies (350+ single-cell studies), 800+ cell types including 80 immune cell types, 500+ diseases, and 300K+ patient samples. AMICA provides deep multiomic single-cell profiling, dynamic functional genomics for multiplexed perturbations, broad curated data from public sources, and unified clinical and immunological annotations for integrative analysis.
Who is Immunai for?
Immunai partners with top biopharmaceutical companies (like AstraZeneca and Teva) and research institutions to discover and advance novel therapeutics. The platform is designed for biopharma companies working on drug discovery and development, particularly in oncology and inflammatory diseases. Immunai also offers a Grand Collaboration Initiative for world-class clinical centers and leading Principal Investigators conducting non-commercial academic research.
What data does Immunai generate?
Immunai generates deep multi-modal profiling including: RNA transcriptome with 1,500+ genes per cell resolution, 80+ surface proteins via CITE-seq proteomic profiling, and T-cell receptor (TCR) repertoire sequencing for lineage tracking. The platform produces fully automated, reproducible single-cell sequencing data that is harmonized, annotated, and interpreted through their machine learning pipeline.
What is the Grand Collaboration Initiative?
The Grand Collaboration Initiative is a high-value, in-kind partnership where Immunai provides fully funded data generation (100-1,000+ samples processed in their high-throughput lab) including scRNA sequencing covering the whole transcriptome, surface proteome (80+ proteins), and TCR repertoire. Clinical partners provide strategic patient cohorts with defined clinical outcomes, anonymized clinical metadata, and scientific leadership. Immunai supplies raw scRNA sequencing data, QC reports, and cell annotations. This is open to non-commercial academic research only.
What sample types does Immunai accept?
Immunai accepts PBMCs (minimum 500K viable cells from whole blood using Sodium Heparin, Sodium Citrate, or K2EDTA tubes), fresh tissue stored in cryopreservation medium (can be cut into smaller fragments if larger than 8mm), and Formalin-Fixed Paraffin-Embedded (FFPE) samples provided as blocks or curls. PBMCs must be isolated using Ficoll gradient within 2-4 hours of collection and controlled-rate frozen at -1°C per minute for long-term storage at -150°C or colder.
How does Immunai validate its findings?
Immunai uses functional genomics to validate ML-driven hypotheses in the lab, ensuring robust and actionable insights. This is the fourth step in their workflow (Generate → Augment → Compute → Validate → Recommend). The platform goes from correlation to causation by combining single-cell technologies with functional genomic validation, allowing them to recapitulate human systems in vitro and confirm that identified immune signals are truly tied to clinical outcomes.
What applications does Immunai support?
Immunai supports target discovery, trial optimization including patient stratification and dose selection, validating therapeutic hypotheses with deep mechanistic insight, prioritizing trial arms or patient subgroups, identifying candidate patient stratification biomarkers, adding confidence to preclinical efficacy and safety evaluation, and identifying targets with the highest potential for therapeutic impact. The platform is particularly used in oncology drug development and inflammatory bowel disease research.
What are the collaboration requirements?
For the Grand Collaboration Initiative, Immunai prioritizes projects with sufficient samples to yield significant scientific results. Studies must comply with regulatory and legal requirements and possess necessary approvals. The research question must contribute to better understanding of the human immune system. The timeline is flexible and determined by cohort size and Immunai's internal resource availability, mutually discussed with each collaborator. Partners retain rights to publish while data enriches the global AMICA atlas.
What costs are covered in the collaboration?
For the Grand Collaboration Initiative, Immunai covers all sequencing costs including scRNA sequencing, surface proteome profiling (80+ proteins), and TCR repertoire sequencing. All other expenses including sample collection, data collection, regulatory fees, shipping, and insurance are the responsibility of the research institute. This is an in-kind partnership where Immunai provides data generation in exchange for access to clinical cohorts and metadata.